Higher dose of schistosomiasis drug shows promise for toddlers
NCT ID NCT03640377
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested two doses (40 vs 80 mg/kg) of praziquantel in 354 children aged 1-4 with schistosomiasis in Uganda. The goal was to find the best dose to cure the infection and improve growth and anemia. Currently, praziquantel is not approved for children under 4, and this trial aims to fill that gap.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
praziquantel
What this could lead to
If successful, this could lead to better dosing guidelines for young children with schistosomiasis, improving cure rates and reducing disease burden.
What could go wrong
This is a Phase II trial with 354 children, so results are still preliminary. Higher doses may cause more side effects, and findings may not apply to all regions or parasite types.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHISTOSOMIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
London School of Tropical Hygiene and Medicine
London, United Kingdom
-
Medical Research Council
Entebbe, 3FC6+Q3C,, Uganda